{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-046481","form_type":"8-K","ticker":"SNWV","cik":"0001417663","company_name":"SANUWAVE Health, Inc.","filed_at":"2024-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.395999+00:00","generated_at":"2026-05-30T02:45:44.819576+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.82,"calibrated_materiality_score":0.82,"confidence":"high","headline":"SANUWAVE Q3 revenue $9.4M (+89% YoY), operating income $2.0M; Q4 guidance 40-50% growth","bullets":["Revenue record of $9.4M, up 89% vs Q3 2023; beat guidance of 65-75% increase.","UltraMist systems sold: 124 in Q3 2024 vs 55 in Q3 2023; consumables revenue $5.4M (+75%).","GAAP operating income $2.0M vs loss of $0.5M in Q3 2023; Adj. EBITDA $2.1M vs ($0.3M).","Net loss $20.7M (driven by derivative liability fair value change); year-to-date loss $18.6M.","Guides Q4 2024 revenue $9.7-10.5M (+40-50% YoY); FY2024 revenue >$32M; 1-for-375 reverse split Oct 18."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-046481","json":"https://secwatch.observer/filing/0001628280-24-046481.json","markdown":"https://secwatch.observer/filing/0001628280-24-046481.md","text":"https://secwatch.observer/filing/0001628280-24-046481.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1417663/000162828024046481/0001628280-24-046481-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1417663/000162828024046481/snwv-20241108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:45:44.819576+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}